{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:53:47Z","timestamp":1788922427854,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82302331"],"award-info":[{"award-number":["82302331"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82402406"],"award-info":[{"award-number":["82402406"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U22A20352"],"award-info":[{"award-number":["U22A20352"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2413500"],"award-info":[{"award-number":["2023YFC2413500"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>Radiofrequency ablation (RFA) is an effective treatment for hepatocellular carcinoma (HCC), but incomplete ablation and recurrence of residual tumors remain significant challenges, partly due to local inflammation and elevated COX-2 levels in the tumor microenvironment. This study aims to investigate the potential of combining celecoxib, a COX-2 inhibitor, with anti-PD-1 monoclonal antibody (\u03b1PD-1) to enhance anti-tumor efficacy and activate immune responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In vitro, ELISA was used to assess the effects of radiofrequency heat treatment and celecoxib on PGE\n                      <jats:sub>2<\/jats:sub>\n                      secretion by Hepa1-6 cells. Scanning electron microscopy, flow cytometry, and CCK-8 assays were employed to evaluate the function and cytotoxic activity of NK92 cells against Hepa1-6 cells. In vivo, orthotopic HCC mice were divided into five groups to evaluate tumor volume, pathology, and survival. The role of celecoxib in the COX-2\/PGE\n                      <jats:sub>2<\/jats:sub>\n                      \/NK cell axis and its impact on NK cell immune function were investigated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In vitro experiments showed that celecoxib reversed PGE\n                      <jats:sub>2<\/jats:sub>\n                      -mediated suppression of NK cell function and cytotoxic activity against HCC cells by inhibiting PGE\n                      <jats:sub>2<\/jats:sub>\n                      secretion. In vivo, orthotopic HCC mice treated with celecoxib and \u03b1PD-1 exhibited significantly reduced tumor volumes, attenuated the infiltration and activation of NK cells, and prolonged survival compared to control groups. The combination therapy also demonstrated a notable abscopal-like effect, inhibiting metastatic tumor growth and activating systemic immunity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Taken together, these findings suggest that celecoxib combined with \u03b1PD-1 represents a promising strategy for treating residual HCC after RFA, with enhanced anti-tumor effects and good safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-025-03582-6","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T11:52:38Z","timestamp":1765972358000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["COX-2\/PGE2 axis blockade with celecoxib enhances anti-PD-1 efficacy by activating natural killer cells for residual hepatocellular carcinoma after radiofrequency ablation"],"prefix":"10.1186","volume":"44","author":[{"given":"Yu","family":"Lei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaowei","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiatong","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licheng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongsen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuansheng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"3582_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6. https:\/\/doi.org\/10.1038\/s41572-020-00240-3.","journal-title":"Nat Rev Dis Primers"},{"key":"3582_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"3582_CR3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41575-019-0229-4","volume":"17","author":"AJ Craig","year":"2020","unstructured":"Craig AJ, von Felden J, Garcia-Lezana T, Sarcognato S, Villanueva A. Tumour evolution in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2020;17:139\u201352. https:\/\/doi.org\/10.1038\/s41575-019-0229-4.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3582_CR4","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76:681\u201393. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.018.","journal-title":"J Hepatol"},{"key":"3582_CR5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3350\/cmh.2017.0006","volume":"23","author":"TW Kang","year":"2017","unstructured":"Kang TW, Lim HK, Cha DI. Aggressive tumor recurrence after radiofrequency ablation for hepatocellular carcinoma. Clin Mol Hepatol. 2017;23:95\u2013101. https:\/\/doi.org\/10.3350\/cmh.2017.0006.","journal-title":"Clin Mol Hepatol"},{"key":"3582_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-23315-5","volume":"12","author":"E Gigante","year":"2022","unstructured":"Gigante E, Haddad Y, Nault JC, et al. Imaging and histological features of tumor biopsy sample predict aggressive intrasegmental recurrence of hepatocellular carcinoma after radiofrequency ablation. Sci Rep. 2022;12:18712. https:\/\/doi.org\/10.1038\/s41598-022-23315-5.","journal-title":"Sci Rep"},{"key":"3582_CR7","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2147\/jhc.S358539","volume":"9","author":"Y Guo","year":"2022","unstructured":"Guo Y, Ren Y, Dong X, Kan X, Zheng C. An overview of hepatocellular carcinoma after insufficient radiofrequency ablation. J Hepatocell Carcinoma. 2022;9:343\u201355. https:\/\/doi.org\/10.2147\/jhc.S358539.","journal-title":"J Hepatocell Carcinoma"},{"key":"3582_CR8","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1007\/s00330-016-4405-4","volume":"27","author":"G Kumar","year":"2017","unstructured":"Kumar G, Goldberg SN, Wang Y, et al. Hepatic radiofrequency ablation: markedly reduced systemic effects by modulating periablational inflammation via cyclooxygenase-2 inhibition. Eur Radiol. 2017;27:1238\u201347. https:\/\/doi.org\/10.1007\/s00330-016-4405-4.","journal-title":"Eur Radiol"},{"key":"3582_CR9","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.immuni.2020.10.020","volume":"53","author":"E Bonavita","year":"2020","unstructured":"Bonavita E, Bromley CP, Jonsson G, et al. Antagonistic inflammatory phenotypes dictate tumor fate and response to immune checkpoint Blockade. Immunity. 2020;53:1215\u2013e12291218. https:\/\/doi.org\/10.1016\/j.immuni.2020.10.020.","journal-title":"Immunity"},{"key":"3582_CR10","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","volume":"172","author":"JP B\u00f6ttcher","year":"2018","unstructured":"B\u00f6ttcher JP, Bonavita E, Chakravarty P, et al. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell. 2018;172:1022\u2013e10371014. https:\/\/doi.org\/10.1016\/j.cell.2018.01.004.","journal-title":"Cell"},{"key":"3582_CR11","doi-asserted-by":"publisher","first-page":"e2350635","DOI":"10.1002\/eji.202350635","volume":"54","author":"C Patterson","year":"2024","unstructured":"Patterson C, Hazime KS, Zelenay S, Davis DM. Prostaglandin E\u2082 impacts multiple stages of the natural killer cell antitumor immune response. Eur J Immunol. 2024;54:e2350635. https:\/\/doi.org\/10.1002\/eji.202350635.","journal-title":"Eur J Immunol"},{"key":"3582_CR12","doi-asserted-by":"publisher","first-page":"e2411082","DOI":"10.1002\/advs.202411082","volume":"12","author":"R Chen","year":"2025","unstructured":"Chen R, Li Z, Fang Z, et al. Chemotherapy-Mediated induction of PD-L1 via SEI1 facilitates myeloma immune evasion. Adv Sci (Weinh). 2025;12:e2411082. https:\/\/doi.org\/10.1002\/advs.202411082.","journal-title":"Adv Sci (Weinh)"},{"key":"3582_CR13","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1146\/annurev-immunol-032414-112049","volume":"34","author":"SH Baumeister","year":"2016","unstructured":"Baumeister SH, Freeman GJ, Dranoff G, Sharpe AH. Coinhibitory pathways in immunotherapy for cancer. Annu Rev Immunol. 2016;34:539\u201373. https:\/\/doi.org\/10.1146\/annurev-immunol-032414-112049.","journal-title":"Annu Rev Immunol"},{"key":"3582_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1070961","volume":"13","author":"Q Li","year":"2022","unstructured":"Li Q, Han J, Yang Y, Chen Y. PD-1\/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. Front Immunol. 2022;13:1070961. https:\/\/doi.org\/10.3389\/fimmu.2022.1070961.","journal-title":"Front Immunol"},{"key":"3582_CR15","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1053\/j.gastro.2021.12.276","volume":"162","author":"GL Su","year":"2022","unstructured":"Su GL, Altayar O, O\u2019Shea R, et al. AGA clinical practice guideline on systemic therapy for hepatocellular carcinoma. Gastroenterology. 2022;162:920\u201334. https:\/\/doi.org\/10.1053\/j.gastro.2021.12.276.","journal-title":"Gastroenterology"},{"key":"3582_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s10495-024-02019-3","volume":"30","author":"J Liang","year":"2025","unstructured":"Liang J, Ma M, Feng W, et al. Anti-PD-L1 blockade facilitates antitumor effects of radiofrequency ablation by improving tumor immune microenvironment in hepatocellular carcinoma. Apoptosis. 2025;30:55\u201368. https:\/\/doi.org\/10.1007\/s10495-024-02019-3.","journal-title":"Apoptosis"},{"key":"3582_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-024-02116-x","volume":"10","author":"X Wu","year":"2024","unstructured":"Wu X, Cao J, Wan X, Du S. Programmed cell death in hepatocellular carcinoma: mechanisms and therapeutic prospects. Cell Death Discov. 2024;10:356. https:\/\/doi.org\/10.1038\/s41420-024-02116-x.","journal-title":"Cell Death Discov"},{"key":"3582_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115351","volume":"166","author":"T Sun","year":"2023","unstructured":"Sun T, Sun B, Cao Y, et al. Synergistic effect of OK-432 in combination with an anti-PD-1 antibody for residual tumors after radiofrequency ablation of hepatocellular carcinoma. Biomed Pharmacother. 2023;166:115351. https:\/\/doi.org\/10.1016\/j.biopha.2023.115351.","journal-title":"Biomed Pharmacother"},{"key":"3582_CR19","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/s0140-6736(11)61347-0","volume":"379","author":"A Forner","year":"2012","unstructured":"Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245\u201355. https:\/\/doi.org\/10.1016\/s0140-6736(11)61347-0.","journal-title":"Lancet"},{"key":"3582_CR20","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","volume":"56","author":"EASL-EORTC clinical","year":"2012","unstructured":"EASL-EORTC clinical. Practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908\u201343. https:\/\/doi.org\/10.1016\/j.jhep.2011.12.001.","journal-title":"J Hepatol"},{"key":"3582_CR21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/s1386-6346(03)00207-9","volume":"27","author":"M Koda","year":"2003","unstructured":"Koda M, Maeda Y, Matsunaga Y, et al. Hepatocellular carcinoma with sarcomatous change arising after radiofrequency ablation for well-differentiated hepatocellular carcinoma. Hepatol Res. 2003;27:163\u20137. https:\/\/doi.org\/10.1016\/s1386-6346(03)00207-9.","journal-title":"Hepatol Res"},{"key":"3582_CR22","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.3748\/wjg.v10.i8.1137","volume":"10","author":"A Ruzzenente","year":"2004","unstructured":"Ruzzenente A, Manzoni GD, Molfetta M, et al. Rapid progression of hepatocellular carcinoma after radiofrequency ablation. World J Gastroenterol. 2004;10:1137\u201340. https:\/\/doi.org\/10.3748\/wjg.v10.i8.1137.","journal-title":"World J Gastroenterol"},{"key":"3582_CR23","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1111\/j.1365-2036.2006.03136.x","volume":"24","author":"A Baldan","year":"2006","unstructured":"Baldan A, Marino D. Percutaneous radiofrequency thermal ablation for hepatocellular carcinoma. Aliment Pharmacol Ther. 2006;24:1495\u2013501. https:\/\/doi.org\/10.1111\/j.1365-2036.2006.03136.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"3582_CR24","doi-asserted-by":"publisher","first-page":"377","DOI":"10.5582\/bst.2022.01373","volume":"16","author":"R Liao","year":"2022","unstructured":"Liao R, Song P, Duan Y, et al. A well-matched marriage of immunotherapy and radiofrequency ablation to reduce the relapse and progression of hepatocellular carcinoma. Biosci Trends. 2022;16:377\u201380. https:\/\/doi.org\/10.5582\/bst.2022.01373.","journal-title":"Biosci Trends"},{"key":"3582_CR25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/hepr.12705","volume":"47","author":"T Ikemoto","year":"2017","unstructured":"Ikemoto T, Shimada M, Yamada S. Pathophysiology of recurrent hepatocellular carcinoma after radiofrequency ablation. Hepatol Res. 2017;47:23\u201330. https:\/\/doi.org\/10.1111\/hepr.12705.","journal-title":"Hepatol Res"},{"key":"3582_CR26","doi-asserted-by":"publisher","first-page":"957","DOI":"10.2165\/00003495-200059040-00017","volume":"59","author":"D Clemett","year":"2000","unstructured":"Clemett D, Goa KL. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs. 2000;59:957\u201380. https:\/\/doi.org\/10.2165\/00003495-200059040-00017.","journal-title":"Drugs"},{"key":"3582_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-024-01203-w","volume":"15","author":"W Gu","year":"2024","unstructured":"Gu W, Zeng D, Zhang C. Discovering the effect of combination of celecoxib and sorafenib on hepatocellular carcinoma. Discov Oncol. 2024;15:321. https:\/\/doi.org\/10.1007\/s12672-024-01203-w.","journal-title":"Discov Oncol"},{"key":"3582_CR28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/s2468-1253(21)00348-4","volume":"7","author":"H Hu","year":"2022","unstructured":"Hu H, Kang L, Zhang J, et al. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7:38\u201348. https:\/\/doi.org\/10.1016\/s2468-1253(21)00348-4.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3582_CR29","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1080\/09553002.2021.1846817","volume":"97","author":"P Zhang","year":"2021","unstructured":"Zhang P, Song E, Jiang M, Song Y. Celecoxib and Afatinib synergistic enhance radiotherapy sensitivity on human non-small cell lung cancer A549 cells. Int J Radiat Biol. 2021;97:170\u20138. https:\/\/doi.org\/10.1080\/09553002.2021.1846817.","journal-title":"Int J Radiat Biol"},{"key":"3582_CR30","doi-asserted-by":"publisher","first-page":"302","DOI":"10.2174\/1389450119666180803121737","volume":"20","author":"N To\u0142oczko-Iwaniuk","year":"2019","unstructured":"To\u0142oczko-Iwaniuk N, Dziemia\u0144czyk-Pakie\u0142a D, Nowaszewska BK, Celi\u0144ska-Janowicz K, Miltyk W. Celecoxib in cancer therapy and prevention - review. Curr Drug Targets. 2019;20:302\u201315. https:\/\/doi.org\/10.2174\/1389450119666180803121737.","journal-title":"Curr Drug Targets"},{"key":"3582_CR31","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1161\/atvbaha.110.207449","volume":"31","author":"E Ricciotti","year":"2011","unstructured":"Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011;31:986\u20131000. https:\/\/doi.org\/10.1161\/atvbaha.110.207449.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3582_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128910","volume":"10","author":"M Ahmed","year":"2015","unstructured":"Ahmed M, Kumar G, Navarro G, et al. Systemic siRNA nanoparticle-based drugs combined with radiofrequency ablation for cancer therapy. PLoS One. 2015;10:e0128910. https:\/\/doi.org\/10.1371\/journal.pone.0128910.","journal-title":"PLoS One"},{"key":"3582_CR33","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1148\/radiol.15141918","volume":"276","author":"N Rozenblum","year":"2015","unstructured":"Rozenblum N, Zeira E, Bulvik B, et al. Radiofrequency ablation: inflammatory changes in the periablative zone can induce global organ effects, including liver regeneration. Radiology. 2015;276:416\u201325. https:\/\/doi.org\/10.1148\/radiol.15141918.","journal-title":"Radiology"},{"key":"3582_CR34","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1158\/2159-8290.Cd-20-0655","volume":"11","author":"B C\u00f3zar","year":"2021","unstructured":"C\u00f3zar B, Greppi M, Carpentier S, et al. Tumor-infiltrating natural killer cells. Cancer Discov. 2021;11:34\u201344. https:\/\/doi.org\/10.1158\/2159-8290.Cd-20-0655.","journal-title":"Cancer Discov"},{"key":"3582_CR35","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aaz2738","author":"CJ Nicolai","year":"2020","unstructured":"Nicolai CJ, Wolf N, Chang IC, et al. NK cells mediate clearance of CD8(+) T cell-resistant tumors in response to STING agonists. Sci Immunol. 2020. https:\/\/doi.org\/10.1126\/sciimmunol.aaz2738.","journal-title":"Sci Immunol"},{"key":"3582_CR36","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nri2604","volume":"9","author":"DH Raulet","year":"2009","unstructured":"Raulet DH, Guerra N. Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat Rev Immunol. 2009;9:568\u201380. https:\/\/doi.org\/10.1038\/nri2604.","journal-title":"Nat Rev Immunol"},{"key":"3582_CR37","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.cell.2015.08.015","volume":"162","author":"S Zelenay","year":"2015","unstructured":"Zelenay S, van der Veen AG, B\u00f6ttcher JP, et al. Cyclooxygenase-Dependent tumor growth through evasion of immunity. Cell. 2015;162:1257\u201370. https:\/\/doi.org\/10.1016\/j.cell.2015.08.015.","journal-title":"Cell"},{"key":"3582_CR38","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1073\/pnas.1612920114","volume":"114","author":"V Prima","year":"2017","unstructured":"Prima V, Kaliberova LN, Kaliberov S, et al. COX2\/mPGES1\/ PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells. Proc Natl Acad Sci U S A. 2017;114:1117\u201322. https:\/\/doi.org\/10.1073\/pnas.1612920114.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3582_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-13484-8","volume":"12","author":"N Maekawa","year":"2022","unstructured":"Maekawa N, Konnai S, Asano Y, et al. Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy. Sci Rep. 2022;12:9265. https:\/\/doi.org\/10.1038\/s41598-022-13484-8.","journal-title":"Sci Rep"},{"key":"3582_CR40","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41401-023-01158-8","volume":"45","author":"H Liu","year":"2024","unstructured":"Liu H, Deng R, Zhu CW, et al. Rosmarinic acid in combination with ginsenoside Rg1 suppresses colon cancer metastasis via co-inhition of COX-2 and PD1\/PD-L1 signaling axis. Acta Pharmacol Sin. 2024;45:193\u2013208. https:\/\/doi.org\/10.1038\/s41401-023-01158-8.","journal-title":"Acta Pharmacol Sin"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03582-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03582-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03582-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:19:37Z","timestamp":1781623177000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-025-03582-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3582"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03582-6","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"1 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The clinical trial and experimental studies were approved by the Institutional Review Board of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (IRB Number: 1019). All participants provided informed consent before enrollment. Animal experiments were approved by the Institutional Review Board of Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology ([2024] IACUC Number:4305).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"321"}}